# Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy

Published: 28-03-2017
Last updated: 13-04-2024

see section 21 & 2.2This trial aims to prove the concept of induction of mucosal healing by BI 655130 add-ontherapy in patients with mild or moderate ulcerative colitis and persisting endoscopic activitydespite pre-existing TNFi treatment.This...

| | |
|---|---|
| **Ethical review** | Approved WMO |
| **Status** | Recruitment stopped |
| **Health condition type** | Gastrointestinal inflammatory conditions |
| **Study type** | Interventional |

## Summary

### ID

NL-OMON47670

**Source**
ToetsingOnline

**Brief title**
BI 655130 in patient with mild to moderate ulcerative colitis.

### Condition

- Gastrointestinal inflammatory conditions

**Synonym**
bowel inflammation, ulcerative colitis

**Research involving**
Human

### Sponsors and support

**Primary sponsor:** Boehringer Ingelheim

**Source(s) of monetary or material Support:** de opdrachtgever Boehringer Ingelheim

## Intervention

**Keyword:** bowel inflammation, TNF inhibitor, ulcerative colitis

## Outcome measures

### Primary outcome

see protocol 5.1.1.

Mucosal healing (MCS mESS *1) at Week 8

### Secondary outcome

See protocol 5.1.2

Clinical remission based on Mayo score (total MCS *2 points, and all subscores

*1 point) at Week 8

Histological remission (Robarts (RHI) score *6) at Week 8

Clinical remission based on Mayo score (total MCS *2 points, and all subscores

*1 point)at Week 12

Mucosal healing (MCS mESS *1) at Week 12

Histological remission (Robarts (RHI) score *6) at Week 12

Modified clinical remission based on Mayo score (total modified MCS *2 and: RBS

=0,

Stool Frequency Score (SFS) =0 or 1 and drop *1 from baseline, AND mESS *1) at

Week 8

Modified clinical remission based on Mayo score (total modified MCS *2 and: RBS

=0,SFS =0 or 1 and drop *1 from baseline, AND mESS *1) at Week 12

# Study description

**Background summary**

see section 1.1

Current biologic treatment of UC is associated with approximately one third of patients each
failing with primary or secondary non-response. In addition, treatment may be limited due to
safety and tolerability issues. Therefore, despite of therapeutic progress, there remains a
significant unmet medical need for new treatment options with an improved safety and
efficacy profile compared to the current therapeutic standard.

BI 655130 is a humanized antagonistic monoclonal IgG1 antibody blocking IL-36*, IL-36*
and IL-36* binding to IL-36R. The IL-36 pathway has been associated with the pathogenesis
of several inflammatory diseases including inflammatory bowel diseases, pustular psoriasis
and psoriasis vulgaris. Emerging preclinical data suggest that IL-36R is a potential target for
the treatment of inflammatory bowel diseases, such as ulcerative colitis.

**Study objective**

see section 21 & 2.2

This trial aims to prove the concept of induction of mucosal healing by BI 655130 add-on
therapy in patients with mild or moderate ulcerative colitis and persisting endoscopic activity
despite pre-existing TNFi treatment.
This trial will explore safety and efficacy of a dose of BI 655130 that was modelled to
achieve the similar exposures as the highest exposures tested and found safe and tolerable in
preceding single and multiple dose studies in healthy subjects, as add-on to pre-existing TNFi
treatment. Secondary and further objectives include assessment of the

pharmacokinetic (PK)
profile of BI 655130 and early exploration of specific biomarkers with
potential usefulness to
predict clinical efficacy or safety outcome or help understand BI 655130`s mode
of action.

**Study design**

see section 3.1 & 3.2

This is a multi-centre, multi-national, randomised, parallel-group,
multiple-doses, placebocontrolled,
double-blind Phase IIa study. Approximately 30 eligible patients with mild to
moderate UC and persisting endoscopic activity will be randomised at 2:1 ratio,
stratified
based on concurrent infliximab use, into treatment arm (approximately 20
patients) versus
placebo (approximately 10 patients).

Overall treatment duration is 12 weeks with additional 24 weeks follow-up.
However, the
timing of start of treatment (V2) during mid cycle of the TNFi dosing cycle,
and primary
endpoint assessment at Week 8 are driven by the notation of spontaneous disease
activity
fluctuations in patients in TNFi. This will reduce the confounding effect of
such fluctuations.
A secondary endpoint assessment after 12 weeks will help to understand the
response kinetics
over a longer induction period.

**Intervention**

See section 4.1- 4.4

treatment with BI655130 or placebo.

**Study burden and risks**

See section 2.3

# Contacts

**Public**

Boehringer Ingelheim

Comeniusstraat 6
Alkmaar 1817 MS
NL
**Scientific**
Boehringer Ingelheim

Comeniusstraat 6
Alkmaar 1817 MS
NL

# Trial sites

## Listed location countries

Netherlands

# Eligibility criteria

**Age**
Adults (18-64 years)
Elderly (65 years and older)

## Inclusion criteria

- 18 * 60 years at screening and randomisation
- Diagnosis of ulcerative colitis *5 months prior to screening
- ReceivingTNFi treatment with doses (i.e. dose and dosing interval) unchanged for *4 months prior to randomisation
- Mild or moderate disease activity, defined as total Mayo Score (MCS) (*10)
- Further criteria apply, refer to protocol section 3.3.2.

## Exclusion criteria

- Prior use of more than one different TNF inhibitor or vedolizumab
- Extensive colonic resection
- Evidence of infection with C. difficile or other intestinal pathogen <28 days prior to screening
- Active or latent tuberculosis

- Further criteria apply, refer to protocol section 3.3.3

# Study design

## Design

| | |
|---|---|
| Study phase: | 2 |
| Study type: | Interventional |
| Intervention model: | Parallel |
| Allocation: | Randomized controlled trial |
| Masking: | Double blinded (masking used) |
| Control: | Placebo |
| Primary purpose: | Treatment |

## Recruitment

NL

| | |
|---|---|
| Recruitment status: | Recruitment stopped |
| Start date (anticipated): | 09-08-2017 |
| Enrollment: | 6 |
| Type: | Actual |

## Medical products/devices used

| | |
|---|---|
| Product type: | Medicine |
| Brand name: | unknown |
| Generic name: | unknown |

# Ethics review

| | |
|---|---|
| Approved WMO Date: | 28-03-2017 |
| Application type: | First submission |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 21-06-2017 |

| | |
|---|---|
| Application type: | First submission |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 10-08-2017 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 18-09-2017 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 02-11-2017 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 06-11-2017 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 18-01-2018 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 08-03-2018 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 04-06-2018 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 08-06-2018 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 27-08-2018 |

| | |
|---|---|
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 12-09-2018 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 23-11-2018 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 21-12-2018 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 02-01-2019 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 11-04-2019 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 10-05-2019 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 21-05-2019 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 06-06-2019 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 06-04-2020 |

| | |
|---|---|
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |
| Approved WMO Date: | 15-04-2020 |
| Application type: | Amendment |
| Review commission: | METC Amsterdam UMC |

# Study registrations

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

| Register | ID |
|---|---|
| EudraCT | EUCTR2016-004572-21-NL |
| ClinicalTrials.gov | NCT03123120 |
| CCMO | NL60945.018.17 |